In what's been labeled the fastest launch of a clinical trial in the history of AstraZeneca, the British pharma will start testing Calquence to examine its effects on the potentially lethal immune overreaction storm associated with COVID-19 infection. The drug is currently approved in the U.S. for mantle cell lymphoma and chronic lymphocytic leukemia. FiercePharma
Wednesday, April 15, 2020
AstraZeneca to test blood cancer drug Calquence in COVID-19 after NIH sees 'some clinical benefit'
In what's been labeled the fastest launch of a clinical trial in the history of AstraZeneca, the British pharma will start testing Calquence to examine its effects on the potentially lethal immune overreaction storm associated with COVID-19 infection. The drug is currently approved in the U.S. for mantle cell lymphoma and chronic lymphocytic leukemia. FiercePharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment